[HTML] mdpi.com

[HTML][HTML] Aflibercept plus FOLFIRI as second-line treatment for metastatic colorectal cancer: a single-institution real-life experience

D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - Cancers, 2021 - mdpi.com
Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …
被引用次数：7 相关文章

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience

D Lavacchi, G Roviello, E Giommoni, L Dreoni… - …, 2021 - search.proquest.com
The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients
with metastatic colorectal cancer (mCRC) who progressed after receiving a standard …
[PDF] academia.edu

[PDF][PDF] Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. Cancers 2021, 13, 3863

D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - 2021 - academia.edu
The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients
with metastatic colorectal cancer (mCRC) who progressed after receiving a standard …
[HTML] nih.gov

[HTML][HTML] Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience

D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - Cancers, 2021 - ncbi.nlm.nih.gov
The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients
with metastatic colorectal cancer (mCRC) who progressed after receiving a standard …

Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience

D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - CANCERS, 2021 - flore.unifi.it
The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients
with metastatic colorectal cancer (mCRC) who progressed after receiving a standard oxali …

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience.

D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - Cancers, 2021 - europepmc.org
The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients
with metastatic colorectal cancer (mCRC) who progressed after receiving a standard …

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience.

D Lavacchi, G Roviello, E Giommoni, L Dreoni… - …, 2021 - search.ebscohost.com
Abstract Simple Summary: The continuum of care for mCRC might include anti-angiogenic
drug as anti-VEGF/VEGFR moAb and recombinant proteins in combination with …

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience

D Lavacchi, G Roviello, E Giommoni, L Dreoni… - …, 2021 - pubmed.ncbi.nlm.nih.gov
The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients
with metastatic colorectal cancer (mCRC) who progressed after receiving a standard …
[PDF] unifi.it

[PDF][PDF] Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. Cancers 2021, 13, 3863

D Lavacchi, G Roviello, E Giommoni, L Dreoni, S Derio… - 2021 - flore.unifi.it
The addition of aflibercept to FOLFIRI has been demonstrated to improve survival in patients
with metastatic colorectal cancer (mCRC) who progressed after receiving a standard …